AHSG and stage 5 chronic kidney disease: We observed in group C that fetuin-A reduced MABP, and this may be due to the improvement in kidney function that leads to a decreased probability of hypertension development and the inhibitory effect of fetuin-A on vascular calcification (52) as lower levels of fetuin-A were associated with higher vascular calcification in patients not yet on renal replacement therapy and patients with end-stage renal disease (13).